关于“在利妥昔单抗时代，乙型肝炎表面抗原阳性是弥漫性大 B 细胞淋巴瘤的一个独立的不良预后因素”。
Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era".
机构信息
Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples, Italy.
Department of Translational and Precision Medicine Sapienza Università di Roma, Rome, Italy.
出版信息
Oncologist. 2021 Jun;26(6):e1083-e1084. doi: 10.1002/onco.13710. Epub 2021 Feb 24.
Abstract
This letter to the editor remarks on the article by Cheng et al., which reported results of a retrospective study that assessed 5‐year progression‐free and overall survival (OS) of 98 patients with hepatitis B surface antigen–seropositive patients receiving R‐CHOP‐21 as remission induction for diffuse large B‐cell lymphoma.
摘要
这封给编辑的信评论了 Cheng 等人的文章，该文章报告了一项回顾性研究的结果，该研究评估了 98 例乙型肝炎表面抗原阳性患者接受 R-CHOP-21 作为弥漫性大 B 细胞淋巴瘤缓解诱导的 5 年无进展生存和总生存（OS）。
相似文献
1
Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era".关于“在利妥昔单抗时代，乙型肝炎表面抗原阳性是弥漫性大 B 细胞淋巴瘤的一个独立的不良预后因素”。
Oncologist. 2021 Jun;26(6):e1083-e1084. doi: 10.1002/onco.13710. Epub 2021 Feb 24.
2
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.在利妥昔单抗时代，乙型肝炎表面抗原阳性是弥漫性大 B 细胞淋巴瘤的独立不良预后因素。
Oncologist. 2020 Sep;25(9):793-802. doi: 10.1634/theoncologist.2019-0756. Epub 2020 Apr 27.
3
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.利妥昔单抗联合化疗治疗乙型肝炎病毒表面抗原阳性弥漫大 B 细胞淋巴瘤患者的预防性抗病毒治疗。
Cancer Sci. 2021 May;112(5):1943-1954. doi: 10.1111/cas.14846. Epub 2021 Mar 18.
4
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.利妥昔单抗时代弥漫性大B细胞淋巴瘤患者血清β2微球蛋白的预后意义
Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.
5
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.恩替卡韦与拉米夫定预防未治疗弥漫性大 B 细胞淋巴瘤接受 R-CHOP 化疗患者乙型肝炎病毒再激活：一项随机临床试验。
JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.
6
The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.在利妥昔单抗时代后弥漫大 B 细胞淋巴瘤中的黏附分子 ICAM-1：与预后重要性和利妥昔单抗耐药性的关系。
Aging (Albany NY). 2020 Dec 3;13(1):181-193. doi: 10.18632/aging.202180.
7
Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.利妥昔单抗联合化疗后弥漫大 B 细胞淋巴瘤患者乙型肝炎病毒再激活的前瞻性分析。
J Clin Oncol. 2010 Dec 1;28(34):5097-100. doi: 10.1200/JCO.2010.29.7531. Epub 2010 Sep 13.
8
Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.复发时外周血淋巴细胞与单核细胞比值可预测利妥昔单抗时代复发或难治性弥漫性大B细胞淋巴瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e91-e97. doi: 10.1016/j.clml.2017.08.096. Epub 2017 Aug 14.
9
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.外周血淋巴细胞/单核细胞比值可预测利妥昔单抗时代滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.
10
High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.REV7高表达是接受利妥昔单抗治疗的弥漫性大B细胞淋巴瘤患者的独立预后指标。
Int J Hematol. 2015 Dec;102(6):662-9. doi: 10.1007/s12185-015-1880-3. Epub 2015 Oct 8.
引用本文的文献
1
Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.台湾地区乙肝病毒和丙肝病毒感染者中非霍奇金淋巴瘤的风险：一项全国性队列研究
Cancers (Basel). 2022 Jan 24;14(3):583. doi: 10.3390/cancers14030583.
本文引用的文献
1
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.在利妥昔单抗时代，乙型肝炎表面抗原阳性是弥漫性大 B 细胞淋巴瘤的独立不良预后因素。
Oncologist. 2020 Sep;25(9):793-802. doi: 10.1634/theoncologist.2019-0756. Epub 2020 Apr 27.
2
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.替诺福韦与拉米夫定预防晚期弥漫大B细胞淋巴瘤患者乙肝病毒再激活的疗效比较
Blood. 2019 Jan 31;133(5):498-501. doi: 10.1182/blood-2018-10-878892. Epub 2018 Dec 7.
3
Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.隐匿性乙肝病毒感染或丙肝抗体阳性的淋巴瘤患者的病毒转归情况
Ann Hepatol. 2017 March-April;16(2):198-206. doi: 10.5604/16652681.1231567.
4
Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.乙型肝炎病毒相关弥漫性大B细胞淋巴瘤：独特的临床特征、不良预后及乙肝表面抗原驱动的起源
Oncotarget. 2015 Sep 22;6(28):25061-73. doi: 10.18632/oncotarget.4677.
5
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.LNH-98.5 试验患者的长期预后，这是第一项比较利妥昔单抗-CHOP 与 DLBCL 患者标准 CHOP 化疗的随机研究：成人淋巴瘤研究组的一项研究。
Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.
Zotero 插件